ImmunoGen (IMGN) Q3 results: Revenues: $13.3M (+22.0%).
Net loss: ($21.8M) (+53.4%); loss/share: ($0.15) (+53.1%); Quick Assets: $204.5M (-22.0%).
2019 guidance: Revenues: $65M – 70M from $40M – 45M.
Key future events: Initiate MIRASOL by year-end.
IND filing for IMGC936 in H1 2020.
Present initial data from FORWARD II platinum agnostic and updated triplet combination studies in mid-2020.
Transition next generation anti-FRĪ± ADC, IMGN151, to pre-clinical development in mid-2020.
Previously: ImmunoGen EPS beats by $0.03, beats on revenue (Nov. 1)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.